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Abstract
Background: The aim of this study was to evaluate the prevalence of beta-lactamase-producing
Capnocytophaga isolates in young children hospitalized in the Pediatric Oncology Department of
Hôpital Sud (Rennes, France) over a ten-year period (1993–2002).
Methods:  In neutropenic children, a periodic survey of the oral cavity allows a predictive
evaluation of the risk of systemic infections by Capnocytophaga spp. In 449 children with cancer,
3,053 samples were collected by oral swabbing and plated on TBBP agar. The susceptibility of
Capnocytophaga isolates to five beta-lactams was determined.
Results: A total of 440 strains of Capnocytophaga spp. were isolated, 309 (70%) of which were
beta-lactamase producers. The beta-lactamase-producing strains were all resistant to cefazolin,
86% to amoxicillin, and 63% to ceftazidime. The proportion of strains resistant to third-generation
cephalosporins remained high throughout the ten-year study, while susceptibility to imipenem and
amoxicillin combined with clavulanic acid was always conserved.
Conclusion: These results highlight the risk of antibiotic failure in Capnocytophaga infections and
the importance of monitoring immunosuppressed patients and testing for antibiotic susceptibility
and beta-lactamase production.
Background
Capnocytophaga spp. are capnophilic, gram-negative fusi-
form rods with gliding motility, common inhabitants of
the oral cavity, but their role as an etiologic agent in juve-
nile periodontitis remains controversial [1]. In immuno-
compromised granulocytopenic patients, a number of
complications, including septicemia, endocarditis, and
peripheric lesions, have been reported [2-4]. Several
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authors have described cases of infections by Capnocy-
tophaga strains resistant to antimicrobial agents [5-8]. An
episode of bacteremia can be the consequence of bacterial
translocation from oral flora. In the absence of bacterial
strain isolation from blood cultures, empiric treatment
might be adjusted according to the susceptibility of strains
isolated during the survey. A sequential survey of the oral
cavity during hospitalization was performed to evaluate
the prevalence of beta-lactamase-producing Capnocy-
tophaga isolates in children hospitalized in the Pediatric
Oncology Department of Hôpital Sud (Rennes, France)
over a ten-year period (1993–2002).
Methods
Samples were collected by swabbing the bucco-pharyn-
geal area of children hospitalized in the Pediatric Oncol-
ogy Department of Hôpital Sud (Rennes, France) [9].
Samples were taken periodically with a minimum of 15
days between each collection. All cancer patients from one
to 17 years were included whatever the type of cancer,
chemotherapy, and clinical situation were. The number of
samples taken per child depended on the oncological dis-
ease (Acute Lymphoblastic Leukemia, Acute Myeloblastic
Leukemia, others), the number of cures, and the number
and length of hospitalizations or treatments. Each sample
was inoculated on TBBP agar plates [4% trypticase soy
agar supplemented with 5% sheep blood, 0.1% yeast
extract (AES Laboratory, France), 100 µg/ml polymyxin
and 50 µg/ml bacitracin (Sigma)] [10], which was then
incubated for two to five days in a 10% CO2 atmosphere.
Isolates were identified on the basis of colony morphol-
ogy, Gram staining, negative catalase and oxidase reac-
tions, API ZYM (BioMérieux, France) [11], and fatty acid
profiles (gas chromatography, SHERLOCK Microbial
Identification System™ MIDI Inc., Newark, DE, USA).
Beta-lactamase production was tested using the qualita-
tive chromogenic cephalosporin disk test (Cefinase®, BBL
Microbiology Systems, Cockeysville, MD, USA). The
results were read after 30 minutes.
Susceptibility testing was determined by standard meth-
ods and break points using the criteria of Bremmelgaard
et al. [12] for screening determinations, and NCCLS [13]
for intermediate/resistant strains. Minimal Inhibitory
Concentrations (MICs) were confirmed by the E-test
method (AES Laboratory, Combourg, France) using the
same incubation conditions. Researchers tested the fol-
lowing antibiotics: amoxicillin, amoxicillin combined to
clavulanic acid, cefazolin, ceftazidime, and imipenem.
Results
Over the ten-year period of this study, researchers ana-
lyzed 3,053 samples from 449 hospitalized children (266
males and 183 females). Capnocytophaga spp (440 strains)
were isolated in 232 children, on TBBP agar and identified
with conventional methods. The annual percentage of
children, who carried a Capnocytophaga strain at least once
varied, with a minimum from 1995 to 1997 (17% and
22%, respectively), and maxima in 1993 (52%), 2001
(58%), and 2002 (61%). These results were also observed
studying the number of Capnocytophaga  isolates in the
same periods: the number of Capnocytophaga  isolates
changed, with a minimum (11, 6%) in 1996 and a maxi-
mum (96, 22%) in 2001, without modification to the iso-
lation and culture techniques (Table 1).
Table 1: Prevalence of Capnocytophaga spp. strains in periodic oral samples from children hospitalized in the Pediatric Oncology 
Department of Hôpital Sud (Rennes, France) from 1993 to 2002
Year Number of children 
included
Number of Capno1 
carriers2 (%)
Number of samples 
collected
Number of Capno iso-
lates (%)
1993 60 31 (52) 305 56 (18)
1994 50 24 (48) 228 49 (21)
1995 45 10 (22) 195 14 (7)
1996 49 8 (16) 198 11 (6)
1997 58 9 (17) 251 13 (5)
1998 62 24 (39) 296 41 (14)
1999 68 24 (35) 267 38 (14)
2000 84 17 (20) 347 31 (9)
2001 85 49 (58) 429 96 (22)
2002 80 49 (61) 537 91 (17)
Total 449 232 (52) 3,053 440 (14)
1: Capnocytophaga
2: Number of children who were Capnocytophaga spp. carriers at least once during the studied period.BMC Infectious Diseases 2005, 5:32 http://www.biomedcentral.com/1471-2334/5/32
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Whatever the number of isolates, there was a high preva-
lence of beta-lactamase-producing strains (70%), with a
varying incidence from 54% in 1996 (based on three out
of 49 children) to 78% in 1995 (similarly, 11/14 isolates
describes 8/45 children) (Figures 1 and 2). The suscepti-
bility of Capnocytophaga strains was always conserved with
imipenem (MIC < 4 µg/ml) and amoxicillin combined
with clavulanic acid (MIC < 4/2 µg/ml). All beta-lacta-
mase producing strains were uniformly resistant to cefazo-
lin (MIC > 8 µg/ml), but the authors noted different levels
of resistance to amoxicillin and ceftazidime (Table 2).
Discussion
In immunocompromised children, a periodic survey of
the oral cavity during hospitalization allows a predictive
evaluation of the risk of systemic infections by Capnocy-
tophaga spp.
In this study, the authors correlated the number of Capno-
cytophaga isolates with the number of child carriers of Cap-
nocytophaga, indicating that protocol was correctly
conducted. A decrease in incidence was observed during
the 1995–1997 period, which could be due to use, in first-
line antibiotic protocols, of beta-lactamase inhibitor com-
binations. During the other time periods, extended-spec-
trum antibiotic were given. Aminoglycosides were always
associated to beta-lactam antibiotics in all protocols from
1993 to 2002. Incidence rates of total extended-spectrum
beta-lactamase producing bacteria (ESBL) in gram-nega-
tive rods responsible for infection in Hôpital Sud (Rennes,
France), calculated for 1,000 days of hospitalization, var-
ied in 2002 from 0.04 to 0.7 depending on the depart-
ment (higher rate in reanimation units) http://
www.cclinouest.comhttp://www.cclinouest.com/PDF/
r_bmr2002_internet.pdf. Interestingly, all Capnocytophaga
Prevalence of beta-lactamase producing Capnocytophaga spp. strains in periodic oral samples from children hospitalized in the  Pediatric Oncology Department of Hôpital Sud (Rennes, France) from 1993 to 2002 Figure 1
Prevalence of beta-lactamase producing Capnocytophaga spp. strains in periodic oral samples from children hospitalized in the 
Pediatric Oncology Department of Hôpital Sud (Rennes, France) from 1993 to 2002.
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spp. strains collected in this study appeared as colonizing
strains, because neither bacteremia, nor other systemic
infections, were observed during this study. Results of
MIC determinations agree with previous works reporting
that beta-lactamases confer a high degree of resistance to
a wide range of beta-lactam antibiotics [14] while having
no effect on imipenem and beta-lactamase-inhibitor com-
binations [15,16]. In a Canadian study, Roscoe et al. [17]
reported that 36% of the strains collected mainly from
clinical sources were beta-lactamase producers, while in a
study in Taiwan, Lin et al. [3] reported that 18% of Capno-
cytophaga strains isolated from patients with bacteremia
were beta-lactam resistant. In our study, the prevalence of
beta-lactamase producers did not increase linearly during
the study period.
A first hypothesis to explain these changes in incidence of
beta-lactamase production could be the impact of current
and previous therapy especially antimicrobial treatments
or pathology, on the oral carriage of Capnocytophaga
(study in progress). In a previous French study, Maury et
al. [18] reported a high prevalence of beta-lactamase-pro-
ducing Capnocytophaga species (75%), which they associ-
ated with previous beta-lactam treatments. Even if
Capnocytophaga spp. belongs to the so-called late coloniz-
ers in the normal flora, meaning that it is more frequently
found in children at 12 months and later, in a follow-up
study of healthy infants from the age of 2 to 12 months,
[19] Nyfors et al. reported a positive correlation between
antimicrobial exposure and beta-lactamase production in
oral anaerobic gram-negative species, while reporting
Percentage of positive beta-lactamase Capnocytophaga spp. carriers, from children hospitalized in the Pediatric Oncology  Department of Hôpital Sud (Rennes, France) from 1993 to 2002 Figure 2
Percentage of positive beta-lactamase Capnocytophaga spp. carriers, from children hospitalized in the Pediatric Oncology 
Department of Hôpital Sud (Rennes, France) from 1993 to 2002.
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only two beta-lactamase-producing C. ochracea isolates. In
a recent contradictory study, [20]Capnocytophaga spp. has
been detected in 1.9% of all episodes of fever and neutro-
penia before antibiotic therapy, versus 0.3% during anti-
microbial treatment.
A second hypothesis to explain these changes in incidence
of beta-lactamase production could be linked to the
immediate environment and close contact. These condi-
tions have a great influence on the composition of the
flora, and coming and going between home and hospital
could modify the children's oral ecosystem. A turnover of
the bacterial population from beta-lactamase-positive to
beta-lactamase-negative strains may occur in young chil-
dren with a developing oral ecosystem.
Another explanation of this high prevalence of beta-lacta-
mase production could be conferred on transfer of encod-
ing-resistance genes. Anaerobic bacteria are known to be
able to exchange genetic material with aerobic bacteria,
even though antibiotic-resistance genes are expressed dif-
ferently in aerobic and anaerobic bacteria [21]. The spread
of antibiotic resistance can also play a great part in noso-
comial infections in neutropenic patients [22]. The high
rate of resistance to third-generation cephalosporins
observed in this study could be due to the dissemination
of an epidemic clone. Some ceftazidime-resistant strains
have the same susceptibility and plasmid profiles (data
not shown). Other authors have described resistant clini-
cal isolates [5,6,14,16], but Rosenau et al. [8] were the first
to characterize a plasmid-encoded TEM extended-spec-
trum beta-lactamase in Capnocytophaga spp. Clavulanate-
sensitive cephalosporinases belonging to class A group 2e
from the classification of Bush et al. [23] have recently
been described [7,24]. They differ by only one or two sub-
stitutions in their sequences (cfxA, Genbank accession No.
U75371; cfxA2, Genbank accession No. AF118110; cfxA3,
Genbank accession No. AF472622). Large transposons
encode all the functions needed for their own conjugation
and for resistance to antimicrobial agents, including third-
generation cephalosporins.
Conclusion
These results show the importance of testing for the anti-
biotic susceptibility of and beta-lactamase production by
clinical Capnocytophaga strains, in which beta-lactamase
production has become very common. In neutropenic
patients, resistance to third-generation cephalosporins
should be taken into consideration upon hospitalization
to adapt the empiric antimicrobial treatment previously
dispensed.
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Table 2: Susceptibility of oral Capnocytophaga spp. isolated from 1993 to 2002 (Hôpital Sud, Rennes, France). Susceptibility testing was 
determined by standard methods and break points according to the criteria of NCCLS [13] and Bremmelgaard et al. [12]
Year Number of Resistant or Intermediate Capnocytophaga strains (%) (Total number of 
Capno strains = 440)
Amoxicillin MIC1> 4 µg/ml Ceftazidime MIC > 4 µg/ml
1993 31 (88) 28 (80)
1994 31 (84) 28 (75)
1995 11 (100) 11 (100)
1996 6 (100) 5 (83)
1997 10 (100) 9 (90)
1998 27 (96) 20 (71)
1999 23 (85) 10 (37)
2000 16 (84) 12 (63)
2001 54 (80) 38 (56)
2002 56 (81) 34 (49)
Total 265 (86) 195 (63)
Note: No strains were resistant to an imipenem and amoxicillin/clavulanic acid combination, and all beta-lactamase-producing strains were resistant 
to cefazolin.
1: Minimal Inhibitory Concentration (µg/ml).Publish with BioMed Central    and   every 
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